1. Home
  2. RGNT vs LITS Comparison

RGNT vs LITS Comparison

Compare RGNT & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RGNT

Regentis Biomaterials Ltd. Ordinary Shares

N/A

Current Price

$3.90

Market Cap

24.6M

Sector

Health Care

ML Signal

N/A

LITS

Lite Strategy Inc.

HOLD

Current Price

$0.88

Market Cap

25.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGNT
LITS
Founded
2004
2000
Country
Israel
United States
Employees
8
4
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.6M
25.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RGNT
LITS
Price
$3.90
$0.88
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.7M
520.2K
Earning Date
05-05-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.23
$0.69
52 Week High
$15.50
$3.03

Technical Indicators

Market Signals
Indicator
RGNT
LITS
Relative Strength Index (RSI) 53.12 47.68
Support Level $1.95 $0.69
Resistance Level $7.80 $1.23
Average True Range (ATR) 2.17 0.08
MACD 0.05 0.02
Stochastic Oscillator 18.79 63.62

Price Performance

Historical Comparison
RGNT
LITS

About RGNT Regentis Biomaterials Ltd. Ordinary Shares

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

About LITS Lite Strategy Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Share on Social Networks: